Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life
2024-513437-21-00Phase 4Authorised
- Sponsor
- Turku University Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cisplatin, Gemmis, oxaliplatin, capecitabine, mesna and 3 more in cancer (5 arms), sponsored by Turku University Hospital. Primary endpoint: Change in speech perception in noise from baseline to 3-4 months after end of initial treatment. Planned start Jul 2024; status: authorised.
02
Drugs
cisplatinGemmisoxaliplatincapecitabinemesna
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-513437-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513437-21-00.